There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keros Therapeutics (KROS – Research Report), ...

Working with a plug-and-play platform that can be applied to multiple therapeutic targets, Cytovia is advancing universal iPSC NK cells and iPSC CAR NK cells. A non-engineered universal candidate ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report ... with a $8.50 average price target. The company has a one-year high of ...

The increasing implication of glial cells in neurodegenerative diseases makes them an appealing addition to iPSC-based model systems for investigating ... has allowed Dr. Fossati’s lab to identify and ...

Clinical grade iPSC lines that are capable of generating high yields of immune cells are genetically engineered using the CRISPR/MAD7 system to target cancer cells, avoid rejection by the host ...